Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934038 | 1.00 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2DNM1 | |
| SCHEMBL22403747 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1892418 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637389 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637391 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL23017054 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637867 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15543930 | 0.92 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL21235537 | 0.92 | CNR1 (0.52) | ALDH1A1CNR1CNR2 | |
| SCHEMBL25359611 | 0.92 | CNR1 (0.52) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2506879-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | Protiva Biotherapeutics Inc. (CA) | 2012-10-10 | — | — | EP | claimed |
| WO-2011066651-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-06-09 | — | — | WO | claimed |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-14 | — | — | US | disclosed |
| US-20260091107-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069677-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | ARCTURUS THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4676446-A1 | NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | ARCTURUS THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12496335-B2 | Zika virus vaccine | CureVac SE (DE) | 2025-12-16 | — | — | US | disclosed |
| US-20190106379-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20190002906-A1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10077232-B2 | Cyclic cationic lipids and methods of use | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-09-18 | — | — | US | disclosed |
| US-9415109-B2 | Stable non-aggregating nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150165039-A1 | STABLE NON-AGGREGATING NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8455455-B1 | Compositions and methods for silencing genes involved in hemorrhagic fever | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-06-04 | — | — | US | disclosed |
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2013-05-09 | — | — | US | disclosed |
| US-20130022649-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-01-24 | — | — | US | disclosed |
| WO-2011141704-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002906-A1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | RNGTT, RNMT, NSUN3 | ALDH1A1 4597/4885CNR1 1848/4885CNR2 2717/4885 |
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | LDLR, CETP, ABHD16A | ALDH1A1 4770/4885CNR1 3732/4885CNR2 3875/4885 |
| US-20130022649-A1 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS | PNLIP, SOD1, APOL1 | ALDH1A1 717/4885CNR1 4291/4885CNR2 4425/4885 |
| US-20260130981-A1 | INFLUENZA VIRUS VACCINES | HLA-B, ADA, HLA-A | ALDH1A1 1766/4885CNR1 4122/4885CNR2 4512/4885 |
| US-12496335-B2 | Zika virus vaccine | DDX5, STING1, MICA | ALDH1A1 4501/4885CNR1 4601/4885CNR2 4532/4885 |
| US-10077232-B2 | Cyclic cationic lipids and methods of use | CETP, LDLR, ABHD16A | ALDH1A1 4771/4885CNR1 3563/4885CNR2 3743/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | ALDH1A1 4885/4885CNR1 3071/4885CNR2 2980/4885 |
| US-12509698-B2 | Synthesis and structure of high potency RNA therapeutics | IGF2BP3, SERPINC1, IGF2BP2 | ALDH1A1 4110/4885CNR1 4602/4885CNR2 4539/4885 |
| US-20190106379-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | LDLR, CETP, ABHD16A | ALDH1A1 4770/4885CNR1 3732/4885CNR2 3875/4885 |
| US-20260091107-A1 | CORONAVIRUS VACCINE | NSUN2, RNMT, RNGTT | ALDH1A1 4061/4885CNR1 4374/4885CNR2 4574/4885 |
| US-20260069677-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | STING1, MAVS, MYD88 | ALDH1A1 4848/4885CNR1 4655/4885CNR2 4347/4885 |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | ADAR, RNGTT, UPF1 | ALDH1A1 4716/4885CNR1 4602/4885CNR2 4694/4885 |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | OTC, OAT, POLRMT | ALDH1A1 4119/4885CNR1 4444/4885CNR2 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.